Altimmune’s Pemvidutide Earns FDA Breakthrough Designation After 24-Week Phase 2b MASH Data
Altimmune’s pemvidutide received FDA Breakthrough Therapy Designation for MASH based on 24-week IMPACT Phase 2b data showing significant MASH resolution without worsening fibrosis. The Company secured FDA alignment on Phase 3 parameters for a 52-week registrational trial incorporating biopsy-based endpoints and the AIM-MASH AI pathology tool.
1. Filing Delay Triggers Nasdaq Compliance Notice
ALT5 Sigma Corporation has announced that it expects to file its Quarterly Report on Form 10-Q for the period ended September 27, 2025 within days, after missing the original deadline. The delayed filing prompted Nasdaq to issue a compliance notice under its late-filing rules. Management attributes the delay to finalizing certain financial disclosures and internal control reviews, and underscores that no restatements of prior-period results are required.
2. Active Engagement with Nasdaq to Restore Compliance
Since receiving the Nasdaq notice, ALT5 has been in continuous communication with the exchange’s compliance team, providing regular updates on the timing and status of its 10-Q submission. CEO Tony Isaac stated that the company has mobilized cross-functional teams—legal, finance and external auditors—to address all outstanding items and expects that the upcoming filing will satisfy Nasdaq’s requirements and lift the compliance designation.
3. Strategic Digital Asset Treasury and Infrastructure Footprint
Founded in 2018, ALT5 operates an institutional-grade global payments, trading and settlement platform and has processed over $5 billion in cryptocurrency transactions to date. The company’s strategic focus on a $WLFI digital asset treasury initiative aims to optimize liquidity management and capitalize on emerging retail and international payment integrations. Leadership believes that timely reporting and restored listing compliance will reinforce investor confidence as ALT5 pursues further ecosystem expansion.